1. Medtech Insight
  2. >>Business
  3. >>R&D

Revita Could ‘Break The Pattern Of Chronic Medication’ For Obesity And T2D – Fractyl

 
• By Ryan Nelson

Based on clinical evidence to date, including newly released findings in 11 patients at one year post-procedure, Fractyl Health believes that by resurfacing and reversing the pathology of the duodenal lining, its Revita system has the potential to become the first disease-modifying therapy that targets a root cause of obesity and type 2 diabetes.

• Source: Shutterstock

Fractyl Health, Inc. released clinical results on 8 August indicating that its Revita outpatient endoscopic procedure could be a weight maintenance and blood sugar solution in “one of the hardest to treat populations.”

Founded in 2010, Burlington, MA-based Fractyl is pioneering new approaches to treat metabolic diseases, including obesity and type 2 diabetes (T2D), recognizing that “despite advances in treatment over the last 50 years, obesity and T2D

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Business

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.